BLS Jobs Up Big: 353K, 3.7% Unemployment
https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-3-7-unemployment?cid=CS-ZC-FT-ahead_of_wall_street-2220369
Feb 02, 2024 - 353K new jobs created for January are nearly double the 180K or so analysts were looking for.
0
Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics
https://www.zacks.com/stock/news/2220250/compared-to-estimates-bristol-myers-bmy-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2220250
Feb 02, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
https://www.zacks.com/stock/news/2218934/bristol-myers-bmy-sblas-for-breyanzi-get-fda-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218934
Jan 31, 2024 - Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.
0
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2218010
Jan 30, 2024 - Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
https://www.zacks.com/stock/news/2216537/analysts-estimate-bristol-myers-squibb-bmy-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2216537
Jan 26, 2024 - Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
https://www.zacks.com/stock/news/2208792/mirati-mrtx-gets-eu-nod-for-krazati-in-kras-mutated-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208792
Jan 11, 2024 - Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
0
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
https://www.zacks.com/stock/news/2207159/exelixis-exel-posts-preliminary-2023-results-to-cut-13-jobs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207159
Jan 08, 2024 - Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
0
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
https://www.zacks.com/stock/news/2205766/agios-agio-up-5-on-upbeat-data-from-thalassemia-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205766
Jan 04, 2024 - Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.
0
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2205605
Jan 04, 2024 - Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
0